Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03286530 · ClinicalTrials.gov registry record · Phase 2
Ruxolitinib + Allogeneic Stem Cell Transplantation in AML
A Phase 2 study of Acute Myeloid Leukemia and Acute Myeloid Leukemia in Remission, sponsored by Massachusetts General Hospital.
- Active
- Registry status
- Phase 2
- Development phase
- 64
- Enrollment target
- 6
- Study locations
NCT03286530 is a Phase 2 study of Acute Myeloid Leukemia and Acute Myeloid Leukemia in Remission that is active but no longer recruiting, run by Massachusetts General Hospital. The registered enrollment target is 64 participants, below the 116-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target (45% lower). The trial reports 6 study locations across 5 states.
The verdict
NCT03286530, a Phase 2 study of Acute Myeloid Leukemia and Acute Myeloid Leukemia in Remission, is active but no longer recruiting, sponsored by Massachusetts General Hospital.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 64 participants
- Enrollment target
- 6
- Study locations
Study Summary
This research study is studying a drug that may help decrease the chances of relapse after Allogeneic Stem Cell transplantation for Acute Myeloid Leukemia. The name of the study drug involved in this study is: • Ruxolitinib
Conditions Studied
Interventions
- DRUG Ruxolitinib
Study Locations (6)
Massachusetts
- Beth Israel Deaconess Medical Center - Boston
- Massachusetts General Hospital - Boston
Missouri
- Washington University - St Louis
Ohio
- The Ohio State University - Columbus
Tennessee
- Vanderbilt University - Nashville
Wisconsin
- Medical College of Wisconsin - Wauwatosa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2017-11-03 |
| Est. Completion | 2026-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03286530
The ClinicalTrials.gov registry entry for NCT03286530 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 116-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target (45% lower). The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Acute Myeloid Leukemia appearing as the primary indexed condition, and to 1 intervention - of which Ruxolitinib is the first listed.
NCT03286530 reports 6 study locations spanning 5 distinct geographic areas - top geographies include Massachusetts, Missouri, Ohio.
Frequently Asked Questions
What is clinical trial NCT03286530 about?
NCT03286530 is a clinical study titled "Ruxolitinib + Allogeneic Stem Cell Transplantation in AML". This research study is studying a drug that may help decrease the chances of relapse after Allogeneic Stem Cell transplantation for Acute Myeloid Leukemia. The name of the study drug involved in this study is: • Ruxolitinib
What is the current status of trial NCT03286530?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 64 participants. The study started on 2017-11-03. Estimated completion is 2026-12.
What conditions does trial NCT03286530 study?
This clinical trial studies the following conditions: Acute Myeloid Leukemia, Acute Myeloid Leukemia in Remission, Allogeneic Stem Cell Transplantation.
What interventions are being tested in trial NCT03286530?
The interventions under investigation include: Ruxolitinib (DRUG).
Who is sponsoring clinical trial NCT03286530?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03286530 being conducted?
This trial has 6 study locations across Massachusetts, Missouri, Ohio, Tennessee, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Myeloid Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Azacitidine or Decitabine With Venetoclax for Acute Myeloid Leukemia With Prior Hypomethylating Agent Failure
RECRUITING · Phase 2
-
Venetoclax + Azacitidine vs. Induction Chemotherapy in AML
RECRUITING · Phase 2
-
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
RECRUITING · Phase 2
-
Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission
RECRUITING · Phase 2
-
A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive Chemotherapy
RECRUITING · Phase 2
-
Venetoclax, Cladribine, Low Dose Cytarabine, and Azacitidine in Treating Patients With Previously Untreated Acute Myeloid Leukemia
RECRUITING · Phase 2
Explore more on PlainTrial
Acute Myeloid Leukemia
All registered trials for this condition
Acute Myeloid Leukemia in Remission
All registered trials for this condition
Massachusetts
All trials with a study site in Massachusetts
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.